This article is more than 5 years old. Information may no longer be current.

Hem/onc appointed NCI board vice chair

Issue: April 25, 2014

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Richard Drachtman

Richard Drachtman, MD, interim chief of pediatric hematology/oncology at Rutgers Cancer Institute of New Jersey, has been appointed vice chair of the NCI Pediatric Central Institutional Review Board (PedCIRB).

Drachtman, also a professor of pediatrics at Rutgers Robert Wood Johnson Medical School, is recognized for his clinical expertise and research in childhood cancer and sickle cell disease. He has served on the NCI PedCIRB board since 2009.

The board reviews NCI-sponsored pediatric clinical trials conducted by the Children’s Oncology Group, the world’s largest pediatric cancer research entity. The panel includes pediatric oncologists, nurses, childhood cancer survivors and consumer advocates.